EcoDrugPlus

Phospholipase A2 Group X

Ensembl ID : ENSLCAG00010002921
Gene Symbol: PLA2G10
4 Cross references
232 Possible Orthologues:

Phospholipase A2, Group Vii (Platelet-Activating Factor Acetylhydrolase, Plasma)

Ensembl ID : ENSLCAG00010004359
Gene Symbol: LOC108895802
4 Cross references
203 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase

Ensembl ID : ENSLCAG00010011527
Gene Symbol: LOC108894876
4 Cross references
246 Possible Orthologues:

Plasminogen

Ensembl ID : ENSLCAG00010009728
Gene Symbol: PLG
2 Cross references
253 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSLCAG00010002870
Gene Symbol: PLAT
1 Cross references
204 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSLCAG00010018849
Gene Symbol: PTAFR
1 Cross references
224 Possible Orthologues:

Platelet-Derived Growth Factor Receptor, Beta Polypeptide

Ensembl ID : ENSLCAG00010003495
Gene Symbol: LOC108899186
4 Cross references
198 Possible Orthologues:

Polo Like Kinase 1

Ensembl ID : ENSLCAG00010022905
Gene Symbol: PLK1
4 Cross references
188 Possible Orthologues:

Polo-Like Kinase 4 (Drosophila)

Ensembl ID : ENSLCAG00010022335
Gene Symbol: LOC108892537
4 Cross references
215 Possible Orthologues:

Poly (Adp-Ribose) Polymerase 1

Ensembl ID : ENSLCAG00010009960
Gene Symbol: LOC108895621
4 Cross references
209 Possible Orthologues:

Poly (Adp-Ribose) Polymerase 2

Ensembl ID : ENSLCAG00010000726
Gene Symbol: PARP2
1 Cross references
185 Possible Orthologues:

Poly (Adp-Ribose) Polymerase Family, Member 3

Ensembl ID : ENSLCAG00010026488
Gene Symbol: PARP3
1 Cross references
196 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).